A Study of KZR-616 in Patients With SLE With and Without Lupus Nephritis

Phase 1/2 Completed 69 enrolled Kezar Life Sciences, Inc.

Non-randomizedSequentialOpen-labelTreatment

Summary

This was a Phase 1b/2, multi-center study in which patients received KZR-616, administered as a subcutaneous (SC) injection weekly for 13 weeks (Phase 1b) or 24 weeks (Phase 2).

Timeline

Start: 2018-02-20
Primary completion: 2022-08-04
Completion: 2022-08-04

Publications

Avasare R, Drexler Y, Caster DJ, Mitrofanova A, Jefferson JA. Management of Lupus Nephritis: New Treatments and Updated Guidelines. Kidney360. 2023 Oct 1;4(10):1503-1511. doi: 10.34067/KID.0000000000000230.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	zetomipzomib	Protein / enzyme biologic	45 mg	Subcutaneous
Subject	zetomipzomib	Protein / enzyme biologic	60 mg	Subcutaneous
Subject	zetomipzomib	Protein / enzyme biologic	75 mg	Subcutaneous

A Study of KZR-616 in Patients With SLE With and Without Lupus Nephritis

Summary

Timeline

Publications

Drugs

Indications